B. Riley Raises Earnings Estimates for Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Equities research analysts at B. Riley upped their Q4 2025 earnings estimates for shares of Eton Pharmaceuticals in a research report issued to clients and investors on Sunday, April 27th. B. Riley analyst M. El-Saadi now anticipates that the company will post earnings of $0.33 per share for the quarter, up from their prior forecast of $0.25. B. Riley has a “Buy” rating and a $24.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share.

ETON has been the subject of several other reports. HC Wainwright restated a “buy” rating and issued a $33.00 price objective on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th. Craig Hallum upped their price objective on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday, March 19th.

Eton Pharmaceuticals Price Performance

Shares of ETON stock opened at $15.98 on Tuesday. Eton Pharmaceuticals has a 1 year low of $3.18 and a 1 year high of $18.41. The stock’s 50 day simple moving average is $14.07 and its two-hundred day simple moving average is $13.08. The company has a market cap of $428.55 million, a PE ratio of -72.64 and a beta of 1.34.

Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.02) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.02). The firm had revenue of $11.65 million during the quarter, compared to analyst estimates of $10.53 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%.

Institutional Investors Weigh In On Eton Pharmaceuticals

Large investors have recently modified their holdings of the business. Baader Bank Aktiengesellschaft acquired a new position in Eton Pharmaceuticals in the fourth quarter valued at about $373,000. Jane Street Group LLC purchased a new position in Eton Pharmaceuticals in the third quarter valued at approximately $90,000. Geode Capital Management LLC lifted its holdings in shares of Eton Pharmaceuticals by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company’s stock valued at $1,637,000 after purchasing an additional 32,365 shares during the last quarter. Anchor Capital Advisors LLC acquired a new position in shares of Eton Pharmaceuticals in the 4th quarter valued at $805,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of Eton Pharmaceuticals during the fourth quarter worth about $147,000. Hedge funds and other institutional investors own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.